O Ondra Health
Semaglutide Tirzepatide ★
How It Works
BMI Calculator Find your body mass index Weight Loss Estimator Project your progress over time Dose Calculator Understand your dosing schedule
FAQ Blog Get Started Patient Portal
Semaglutide Tirzepatide ★
How It Works
BMI Calculator Weight Loss Estimator Dose Calculator
FAQ Blog
Get Started Patient Portal

ONDRA HEALTH

About Us

Ondra Health was built to make accessing treatment feel clear, straightforward, and grounded in real care — not marketing. It's independently owned and operated, combining clinical experience and operational expertise to create a more thoughtful way to navigate GLP-1 treatment.

Why We Built This

This space has become more complicated than it needs to be.

Between inconsistent pricing, unclear information, and platforms that feel more like subscription products than healthcare, it's often difficult to understand what you're actually signing up for.

From a clinical perspective, we've also seen how important it is for treatment to be individualized — not standardized or rushed.

Ondra was built to simplify both sides of that.

What Makes Ondra Different

Our approach is intentionally simple:

  • Transparent, upfront pricing
  • No unnecessary add-ons or bundled services
  • Provider-led care based on your individual health profile
  • Medications fulfilled through state-licensed compounding pharmacies

We focus on removing friction — not adding to it.

How Care Works

Ondra Health is a platform that connects patients with independent, licensed healthcare providers.

All medical evaluations, prescriptions, and treatment decisions are made by those providers. Medications are fulfilled by regulated compounding pharmacies based on your prescription and location.

Our role is to make that process easier to access, easier to understand, and easier to manage.

Care & Communication

Access is only part of the experience — communication matters just as much.

You should be able to ask questions, understand your options, and feel supported throughout your treatment — not left figuring things out on your own.

We've built Ondra to feel more direct, responsive, and transparent than traditional platforms. As we grow, our focus is to maintain that level of clarity and support across every interaction.

Built to Be Clear

Ondra isn't built around trends, branding, or upsells.

It's built to be something you can rely on — clear information, straightforward access, and honest communication from start to finish.

A Note From Us

Thank you for taking the time to learn about Ondra.

If you choose to move forward with us, our goal is to provide a clear, responsive, and high-quality experience — the kind of care and service we would expect ourselves.

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"/> <meta name="viewport" content="width=device-width, initial-scale=1.0"/> <title>Semaglutide and Fertility: What Women Need to Know | Ondra Health</title> <!-- CMS FIELDS Name: Semaglutide and Fertility: What Women Need to Know Slug: semaglutide-fertility Excerpt: Semaglutide is not recommended during pregnancy or when actively trying to conceive — but weight loss itself can meaningfully improve fertility. Here is what the evidence says about timing, stopping the medication, and what to discuss with your provider. Category: Women's Health Read Time: 7 min read Meta Title: Semaglutide and Fertility: What Women Need to Know (2026) Meta Description: Thinking about getting pregnant while on semaglutide? Learn the official guidance, how long to stop before conception, and how GLP-1-driven weight loss affects fertility outcomes. --> </head> <body> <section class="ondra-article-page"> <div class="ondra-article-hero"> <div class="ondra-article-container"> <div class="ondra-article-meta-row"> <span class="ondra-meta-pill">⏱ 7 min read</span> <span class="ondra-meta-pill">🏷 Women's Health</span> </div> <h1 class="ondra-article-title">Semaglutide and Fertility: What Women Need to Know</h1> <p class="ondra-article-intro">For women of reproductive age on semaglutide, questions about fertility, conception timing, and the safety of the medication during pregnancy are among the most important — and least straightforwardly answered — topics in GLP-1 care. Here is what the current evidence and clinical guidelines actually say, and what the conversation with your provider should cover.</p> </div> </div> <div class="ondra-article-container ondra-article-body"> <div class="ondra-article-layout" id="ondraArticleLayout"> <div class="ondra-article-main" id="ondraArticleMain"> <a href="/blog" class="ondra-back-link">← Back to all articles</a> <div class="ondra-takeaways-card"> <h2 class="ondra-card-heading">Key takeaways</h2> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>Semaglutide is not recommended for use during pregnancy. Current clinical guidelines advise stopping semaglutide at least 2 months before attempting to conceive.</p> </div> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>Weight loss itself — independent of the medication — improves fertility outcomes for women with obesity, including ovulation regularity, IVF success rates, and risk of pregnancy complications.</p> </div> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>Semaglutide may increase the effectiveness of oral contraceptives by slowing gastric emptying — meaning women on GLP-1s using oral birth control should be aware of this interaction.</p> </div> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>If you become pregnant while on semaglutide, stop immediately and contact your OB or prescribing provider.</p> </div> </div> <div class="ondra-section"> <h2>Is semaglutide safe during pregnancy?</h2> <p>The direct answer is: there is not enough human safety data to know, and animal studies have shown fetal harm at doses relevant to human exposure. Based on this, both the FDA prescribing information for Wegovy (Novo Nordisk, 2021) and current clinical guidelines from the Obesity Medicine Association recommend against using semaglutide during pregnancy.</p> <p>Animal studies using semaglutide in pregnant rats and rabbits demonstrated dose-dependent embryo-fetal toxicity, including structural abnormalities and reduced fetal growth, at exposures comparable to those in humans. These findings do not prove the same effects would occur in humans — rodent reproductive pharmacology does not always translate directly — but they are sufficient to categorize the medication as not recommended during pregnancy under current evidence.</p> <p>No large-scale prospective human pregnancy safety studies have been completed for semaglutide. Registry data is accumulating, but it is not yet sufficient to change the clinical guidance. The position of all major professional bodies is the same: do not use GLP-1 receptor agonists during pregnancy.</p> </div> <div class="ondra-section"> <h2>When should I stop semaglutide before trying to conceive?</h2> <p>The current clinical recommendation is to discontinue semaglutide at least <strong>2 months (approximately 8 weeks) before attempting conception</strong>. This recommendation is based on semaglutide's elimination half-life of approximately 7 days — it takes approximately 5 half-lives (about 5 weeks) for the medication to clear the body to less than 3% of peak concentration. The 2-month window provides a buffer above that clearance timeline.</p> <p>This guidance appears in the Wegovy prescribing information (FDA, 2021) and is consistent with guidance from the American College of Obstetricians and Gynecologists (ACOG) on GLP-1 medications in reproductive-age women.</p> <div class="ondra-info-card"> <p class="ondra-info-title">Planning the timing</p> <p>If you are planning to conceive in the next 6–12 months, discuss this with your Ondra provider in advance. You can use the remaining months of treatment to reach as much of your weight loss goal as possible before stopping — weight loss achieved before stopping semaglutide does not reverse immediately, and some patients maintain meaningful improvements in weight and metabolic health for months to years after discontinuation if they have adopted supportive lifestyle habits during treatment.</p> </div> </div> <div class="ondra-section"> <h2>How weight loss from semaglutide improves fertility</h2> <p>While semaglutide itself should not be used during pregnancy or active attempts to conceive, the weight loss it produces can meaningfully improve fertility outcomes. This is a well-established area of reproductive medicine.</p> <div class="ondra-info-card"> <p class="ondra-info-title">Ovulation and menstrual regularity</p> <p>Excess adipose (fat) tissue disrupts the hormonal signaling involved in ovulation. Elevated estrogen produced by fat cells interferes with the hypothalamic-pituitary-ovarian axis, which regulates the menstrual cycle. Women with obesity have higher rates of anovulation (failure to ovulate) and irregular cycles. A meta-analysis published in <em>Human Reproduction Update</em> (Maheshwari et al., 2007) found that even a 5–10% reduction in body weight can restore ovulatory function in many women with obesity-related anovulation.</p> </div> <div class="ondra-info-card"> <p class="ondra-info-title">PCOS and insulin resistance</p> <p>Polycystic ovary syndrome (PCOS) — the most common cause of anovulatory infertility in women — is closely linked to insulin resistance and is highly prevalent in women with obesity. GLP-1 medications improve insulin sensitivity directly, and the weight loss they produce further reduces hyperandrogenism and restores ovulatory cycles. Multiple studies in women with PCOS on GLP-1 agonists have shown improvements in menstrual regularity and ovulation rates. See Ondra's dedicated <a href="https://ondra.health/blog/semaglutide-pcos">semaglutide and PCOS guide</a> for more detail.</p> </div> <div class="ondra-info-card"> <p class="ondra-info-title">IVF outcomes</p> <p>For women undergoing IVF, obesity is associated with lower implantation rates, higher miscarriage rates, and lower live birth rates per cycle. A systematic review in <em>Reproductive BioMedicine Online</em> (Rittenberg et al., 2011) found significantly lower live birth rates per IVF cycle in women with obesity compared to normal-weight controls. Pre-conception weight loss — including through GLP-1 treatment — has been associated with improved IVF outcomes in observational studies, though randomized trial data specific to GLP-1 pre-IVF weight loss is limited.</p> </div> <div class="ondra-info-card"> <p class="ondra-info-title">Pregnancy complication risk</p> <p>Obesity in pregnancy is independently associated with increased risks of gestational diabetes, preeclampsia, cesarean delivery, preterm birth, and macrosomia (large for gestational age infant). Pre-pregnancy weight loss reduces these risks proportionally. Achieving a lower body weight before conception — whether through GLP-1 treatment stopped at the appropriate time or other means — is associated with meaningfully better maternal and fetal outcomes.</p> </div> </div> <div class="ondra-section"> <h2>Semaglutide and oral contraceptive effectiveness</h2> <p>This interaction deserves specific attention for women on both semaglutide and oral contraceptives (OCs). Semaglutide slows gastric emptying, which can delay the absorption of oral medications including contraceptive pills. The clinical significance of this interaction for contraceptive efficacy is not fully established in the literature, but Novo Nordisk's Wegovy prescribing information notes that women on oral contraceptives may want to discuss this with their prescriber.</p> <p>Importantly, the interaction cuts both ways: while slowed absorption may theoretically reduce peak plasma levels of OC hormones, the clinical relevance depends on the specific formulation. There are also anecdotal reports of women on GLP-1s experiencing unintended pregnancies while on oral contraceptives — though causality has not been established. Women on both semaglutide and oral contraceptives should discuss contraceptive reliability with their OB or prescribing provider, and may wish to consider a non-oral contraceptive method (IUD, implant, patch) to eliminate any absorption-related uncertainty.</p> </div> <div class="ondra-section"> <h2>If you become pregnant while on semaglutide</h2> <div class="ondra-info-card"> <p class="ondra-info-title">What to do immediately</p> <p>Stop semaglutide immediately. Contact your OB-GYN or prescribing provider as soon as possible to discuss your options and establish prenatal care. There is currently no evidence that brief early inadvertent exposure to semaglutide (before pregnancy is known) definitively causes harm in humans — but the medication is not considered safe for ongoing use during pregnancy. Novo Nordisk maintains a pregnancy exposure registry (1-800-727-6500) for women who become pregnant while using Wegovy or Ozempic, which collects data to better understand real-world pregnancy outcomes.</p> </div> </div> <div class="ondra-section"> <h2>Frequently asked questions</h2> <div class="ondra-faq-item"> <h3>Can semaglutide affect fertility?</h3> <p>Semaglutide itself has not been shown to reduce fertility — the concern is about its use during pregnancy, not in the pre-conception period. In fact, the weight loss produced by semaglutide can improve fertility by restoring ovulatory cycles, reducing insulin resistance, and improving hormonal balance. The recommendation is to stop the medication 2 months before trying to conceive, not to avoid it entirely before you are ready for pregnancy.</p> </div> <div class="ondra-faq-item"> <h3>How long should I stop semaglutide before getting pregnant?</h3> <p>Current clinical guidance recommends stopping semaglutide at least 2 months (approximately 8 weeks) before attempting conception. This is based on semaglutide's 7-day elimination half-life and provides a clearance buffer beyond the 5-half-life standard. Plan this in advance with your Ondra provider so you can optimize treatment time before stopping.</p> </div> <div class="ondra-faq-item"> <h3>Does semaglutide affect my birth control?</h3> <p>Semaglutide can slow the absorption of oral contraceptive pills due to delayed gastric emptying. The clinical significance for contraceptive efficacy is not fully established, but women on both medications should discuss this interaction with their provider. Non-oral contraceptive methods (IUD, hormonal implant, patch, ring) are not affected by this mechanism and may provide more reliable protection for women on GLP-1 medications.</p> </div> <div class="ondra-faq-item"> <h3>Can I take semaglutide while trying to get pregnant?</h3> <p>No. Clinical guidelines from Novo Nordisk (Wegovy prescribing information, FDA 2021) and major professional medical organizations recommend against using semaglutide while attempting to conceive. The medication should be stopped at least 2 months before trying for a pregnancy. Use this time to optimize the weight loss benefits you have already achieved and establish supportive habits that will persist after stopping the medication.</p> </div> <div class="ondra-faq-item"> <h3>Will I gain weight after stopping semaglutide for pregnancy?</h3> <p>Some weight regain after stopping semaglutide is expected — the SURMOUNT-4 trial demonstrated that patients who discontinued tirzepatide regained approximately 50% of lost weight within 52 weeks without additional intervention. However, patients who have adopted durable dietary and lifestyle habits during treatment tend to regain less. Pre-conception weight loss — even if partially regained — still meaningfully reduces the risk of obesity-related pregnancy complications compared to entering pregnancy at a higher starting weight.</p> </div> </div> <p class="ondra-disclaimer">† This article is for informational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. This content should not substitute for consultation with your OB-GYN or prescribing provider regarding reproductive planning. Clinical data sourced from: Wegovy® FDA prescribing information (Novo Nordisk, 2021); Maheshwari et al., <em>Human Reproduction Update</em>, 2007; Rittenberg et al., <em>Reproductive BioMedicine Online</em>, 2011; SURMOUNT-4 trial (Aronne et al., <em>JAMA</em>, 2024). Wegovy® and Ozempic® are registered trademarks of Novo Nordisk. Ondra Health is not affiliated with Novo Nordisk.</p> </div> <aside class="ondra-article-sidebar" id="ondraSidebarCol"> <div class="ondra-sidebar-track" id="ondraSidebarTrack"> <div class="ondra-sidebar-card-wrap" id="ondraSidebarWrap"> <div class="ondra-sidebar-card" id="ondraSidebarCard"> <div class="ondra-sidebar-top"> <p class="ondra-sidebar-eyebrow">ONDRA HEALTH</p> <h3>Provider-guided GLP-1 care for women</h3> </div> <div class="ondra-sidebar-bottom"> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Semaglutide from $113/mo, tirzepatide from $183/mo</p></div> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Licensed provider reviews your individual intake</p></div> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Only charged if approved</p></div> <a href="https://intake.ondra.health/start-online-visit/glp1" class="ondra-sidebar-button" target="_blank" rel="noopener noreferrer">Start your intake <span aria-hidden="true">→</span></a> <p class="ondra-sidebar-note">Only charged if a provider approves your treatment.</p> </div> </div> </div> </div> </aside> </div> </div> </section> </body> </html>
O
Ondra Health

Personalized GLP-1 treatment plans, guided by licensed providers who care about your journey.

Verify Approval for www.ondra.health

Navigate

Home Patient Portal

Treatments

Semaglutide Tirzepatide Service Areas

Tools

BMI & Weight Loss GLP-1 Eligibility Weight Loss Timeline Calorie Calculator Protein & Water Dose Calculator

Resources

FAQ Blog GLP-1 Reference Pharmacy Partners Contact Us

Legal

Terms of Service Privacy Policy Refund Policy HIPAA Policy Safety Information
Leave Us a Review
Review Us on Trustpilot

© 2026 Ondra Health Inc. All rights reserved.

Ondra Health provides access to telehealth services and compounded medications through licensed providers and pharmacies.